Palvella Therapeutics (PVLA) Common Equity (2013 - 2026)
Palvella Therapeutics (PVLA) posted quarterly Common Equity of $232.3 million for Q1 2026, up 318.0% year-over-year from $55.6 million in Q1 2025, and up 730.19% quarter-over-quarter from $28.0 million in Q4 2025.
Palvella Therapeutics (PVLA) Common Equity (2013 - 2026) Analysis & Trends
Palvella Therapeutics (PVLA) has reported Common Equity for 14 consecutive years, with $232.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity rose 318.0% year-over-year to $232.3 million; the TTM figure through Mar 2026 stood at $232.3 million (up 318.0% YoY), while the FY2025 annual figure was $28.0 million, down 55.3% from the prior year.
- Common Equity grew to $232.3 million in Q1 2026 per PVLA's latest filing, from $28.0 million in the prior quarter.
- Across five years, Common Equity topped out at $232.3 million in Q1 2026 and bottomed at -$93.8 million in Q4 2022.
- Historically, Common Equity has averaged $13.9 million across 5 years, with a median of $30.5 million in 2023.
- Annual changes were most pronounced in 2023 — Common Equity soared 5722.52% — and 2024, when it plunged 597.3%.
- Palvella Therapeutics' Common Equity stood at -$93.8 million in 2022, then increased by 20.57% to -$74.5 million in 2023, then surged by 184.06% to $62.6 million in 2024, then slumped by 55.3% to $28.0 million in 2025, then jumped by 730.19% to $232.3 million in 2026.
- Business Quant data shows PVLA's Common Equity at $232.3 million in Q1 2026, $28.0 million in Q4 2025, and $38.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Palvella Therapeutics | 2.25 Bn | 1.93 Bn | - | 216.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 216.87 Mn |
| Mar 31, 2026 | 232.31 Mn |
| Dec 31, 2025 | 27.98 Mn |
| Sep 30, 2025 | 38.68 Mn |
| Jun 30, 2025 | 47.78 Mn |
| Mar 31, 2025 | 55.58 Mn |
| Dec 31, 2024 | 62.61 Mn |
| Sep 30, 2024 | -87.40 Mn |
| Jun 30, 2024 | -80.83 Mn |
| Mar 31, 2024 | -76.87 Mn |
| Dec 31, 2023 | -74.48 Mn |
| Sep 30, 2023 | 30.51 Mn |
| Jun 30, 2023 | 40.50 Mn |
| Mar 31, 2023 | 15.46 Mn |
| Dec 31, 2022 | -93.78 Mn |
| Sep 30, 2022 | 524,000.00 |
| Jun 30, 2022 | 44.37 Mn |
| Mar 31, 2022 | 53.45 Mn |
| Dec 31, 2021 | 50.76 Mn |
| Sep 30, 2021 | 53.85 Mn |